Results 21 to 30 of about 16,301 (208)

Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice [PDF]

Diabetes & Metabolism Journal, 2022
Background Non-alcoholic fatty liver disease (NAFLD) has been increasing in association with the epidemic of obesity and diabetes. Peroxisomes are single membrane-enclosed organelles that play a role in the metabolism of lipid and reactive oxygen species.
Songling Jiang, Md Jamal Uddin, Xiaoying Yu, Lingjuan Piao, Debra Dorotea, Goo Taeg Oh, Hunjoo Ha   +6 more
doaj   +1 more source

The effects of simvastatin and fenofibrate on malondialdehyde and reduced glutathione concentrations in the plasma, liver, and brain of normolipidaemic and hyperlipidaemic rats

Arhiv za Higijenu Rada i Toksikologiju, 2023
The objective of study was to investigate the effects of different doses of simvastatin and fenofibrate on malondialdehyde (MDA) and reduced glutathione (GSH) in the plasma, liver, and brain tissue of male normolipidaemic and hyperlipidaemic rats ...
Vukšić Antonija, Rašić Dubravka, Žunec Suzana, Božina Tamara, Konjevoda Paško, Lovrić Jasna, Bilušić Marinko, Bradamante Vlasta   +7 more
doaj   +1 more source

Fenofibrate Ameliorated Systemic and Retinal Inflammation and Modulated Gut Microbiota in High-Fat Diet-Induced Mice

Frontiers in Cellular and Infection Microbiology, 2022
Fenofibrate, as a lipid-lowering drug, has been reported to have a protective effect on the retina independent with plasma lipid levels. This study aimed to investigate that the ameliorative effects of fenofibrate on systemic and retinal inflammation, as
Xue Wang, Xue Wang, Chaofeng Yu, Xiaomei Liu, Jiasong Yang, Jiasong Yang, Yuliang Feng, Yajun Wu, Yali Xu, Yihua Zhu, Wensheng Li, Wensheng Li   +11 more
doaj   +1 more source

Beneficial Effect of Fenofibrate and Silymarin on Hepatic Steatosis and Gene Expression of Lipogenic and Cytochrome P450 Enzymes in Non-Obese Hereditary Hypertriglyceridemic Rats

Current Issues in Molecular Biology, 2022
The efficacy of fenofibrate in the treatment of hepatic steatosis has not been clearly demonstrated. In this study, we investigated the effects of fenofibrate and silymarin, administered as monotherapy and in combination to existing hepatic steatosis in ...
Rostislav Vecera, Martin Poruba, Martina Hüttl, Hana Malinska, Olena Oliyarnyk, Irena Markova, Zuzana Racova, Jan Soukop, Ludmila Kazdova   +8 more
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Fenofibrate diminishes the self-renewal and metastasis potentials of oral carcinoma stem cells through NF-κB signaling

Journal of the Formosan Medical Association, 2022
Background/Purpose: NF-κB family of transcription factors are the major contributors to malignant tumor progression, maintenance of cancer stemness, and enhancement of chemoresistance.
Tzu-Rong Su, Cheng-Chia Yu, Shih-Chi Chao, Chun-Chung Huang, Yi-Wen Liao, Pei-Ling Hsieh, Chuan-Hang Yu, Shih-Shen Lin   +7 more
doaj   +1 more source

Fenofibrate and losartan [PDF]

Annals of the Rheumatic Diseases, 2003
Should we take advantage of their uricosuric properties in clinical practice? The interesting study published in this issue of the journal by Takahashi et al sheds light on two drugs, losartan and fenofibrate, which have hypouricaemic properties, in addition to their main therapeutic effects.1 Losartan potassium is an orally active angiotensin II ...
openaire   +2 more sources

Dietary fenofibrate attenuated high-fat-diet-induced lipid accumulation and inflammation response partly through regulation of pparα and sirt1 in juvenile black seabream (Acanthopagrus schlegelii) [PDF]

, 2020
An 8-week feeding trail was conducted in Acanthopagrus schlegelii with an initial body weight of 8.34±0.01g. Three isonitrogenous diets were formulated, (1) Control: medium-fat diet (12%); (2) HFD: high-fat diet (18%); (3) HFD+FF: high-fat diet with ...
Zhu, Tingting, Shen, Yuedong, Yuan, Ye, Luo, Jiaxiang, Pan, Tingting, Jiao, Lefei, Jin, Min, Tocher, Douglas, Sun, Peng, Li, Xuejiao, Zhou, Quicun, Betancor, Monica   +11 more
core   +1 more source

Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice

Frontiers in Pharmacology, 2022
Fenofibrate is widely used in clinical therapy to effectively ameliorate the development of non-alcoholic fatty liver disease (NAFLD); however, its specific molecular mechanism of action remains largely unknown.
Dan Zhang, Shanzhuang Niu, Yicheng Ma, Hang Chen, Yu Wen, Mingke Li, Bo Zhou, Yi Deng, Chunjing Shi, Guangyu Pu, Meng Yang, Xianmei Wang, Chenggang Zou, Yuanli Chen, Lanqing Ma   +14 more
doaj   +1 more source

Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression

Journal of Lipid Research, 2007
In addition to efficiently decreasing VLDL-triglycerides (TGs), fenofibrate increases HDL-cholesterol levels in humans. We investigated whether the fenofibrate-induced increase in HDL-cholesterol is dependent on the expression of the cholesteryl ester ...
Caroline C. van der Hoogt, Willeke de Haan, Marit Westerterp, Menno Hoekstra, Geesje M. Dallinga-Thie, Johannes A. Romijn, Hans M.G. Princen, J. Wouter Jukema, Louis M. Havekes, Patrick C.N. Rensen   +9 more
doaj   +1 more source